uniQure N.V. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
uniQure announced FDA acceptance of its BLA for ifezuntirgene inilparvovec (AMT-130), a gene therapy for Huntington's disease, under Accelerated Approval pathway with Priority Review. FDA set PDUFA target action date of May 1, 2027. If approved, it would be the first disease-modifying treatment for Huntington's disease. The BLA is supported by 36-month Phase I/II data (51 patients dosed total); confirmatory trial (~200 patients, 2:1 randomized design) screening to begin by end of 2026.
Why this rating
Significant near-term catalyst for ~$765M market-cap biotech: regulatory milestone de-risks path to first-in-class therapy; 18-month timeline to potential approval is material; confirmatory trial dependency and post-approval uncertainties create execution risk.
Price action (we called it positive)
before filing · preread $28.40 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.